<DOC>
	<DOCNO>NCT00777595</DOCNO>
	<brief_summary>The purpose study evaluate effect single dose therapeutic supratherapeutic dos inhale CHF 4226 pMDI ventricular repolarization healthy subject compare placebo .</brief_summary>
	<brief_title>Evaluation Possible Effects QTc Interval CHF 4226 pMDI Healthy Volunteers</brief_title>
	<detailed_description>The secondary purpose study 1 ) determine relationship duration QTc interval plasma concentration carmoterol ; 2 ) expand available information plasma pharmacokinetics urine excretion inhale carmoterol propose therapeutic supra-therapeutic dos ; 3 ) generate additional safety information .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy adult male female subject , 1855 year age provide write informed consent . A body mass index ( BMI ) 18 30 , inclusive . A normal blood pressure ( &lt; 140mmHg systolic &lt; 90mmHg diastolic ) A normal 12lead ECG ( QTcF interval &lt; 450msec male &lt; 470msec female ) . A serum potassium &lt; /= 4.0mEq/L . A calculated creatinine clearance &gt; 80mL/min . Male subject must agree use medically acceptable contraceptive ( abstain sexual intercourse , use condom spermicide ) , vasectomy least 6 month prior study participation partner childbearing potential . A history presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . A history sensitivity allergy quinolone class antibiotic and/or beta 2 adrenergic receptor agonist . Clinically significant screening result ( laboratory profile , medical history , ECGs , physical exam ) . Hemoglobin normal reference range test laboratory . Abuse alcohol substance . Current use tobacco product . Subjects positive laboratory test result hepatitis B , hepatitis C , HIV , control substance , cotinine alcohol . Any prescription medication take within 14 day ( 5 elimination halflives , whichever long ) Study Day 2 , take overthecounter medication , include topical medication , vitamin , herbal dietary supplements/remedies ( e.g. , Saint John 's Wort Milk Thistle ) , within 14 day Study Day 2 , plan concomitant medication study ( except acetaminophen 2g/day ) , exception hormonal birth control medication hormone replacement therapy female . A history additional risk factor Torsade de Pointes ( e.g. , hypokalemia , history drown survival , family history Long QT Syndrome , family history Short QT Syndrome , family history unexplainable early sudden death ) . Subject pregnant lactate female , female risk pregnancy ( i.e. , use adequate contraceptive method : surgical sterilization [ e.g. , bilateral tubal ligation ] , hormonal contraception [ implantable , patch , oral ] , IUD , doublebarrier method [ double combination : male female condom spermicidal gel , diaphragm , sponge , cervical dap ] _ . Participation study investigational drug within 30 day prior baseline ECG . Any condition , judgment Investigator , would place subject undue risk , potentially compromise result interpretation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>QTc</keyword>
	<keyword>CHF 4226 HFA</keyword>
	<keyword>pMDI</keyword>
	<keyword>Carmoterol</keyword>
</DOC>